Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 17/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442042 | 0.91 | PKMYT1 (0.65) | PKMYT1GSK3BCDK2 | |
| SCHEMBL13105481 | 0.89 | SLC2A1 (0.57) | PKMYT1GSK3BCDK2CDK4DYRK1A | |
| SCHEMBL3441818 | 0.84 | PKMYT1 (0.55) | PKMYT1GSK3BCDK2 | |
| SCHEMBL13105474 | 0.81 | SLC2A1 (0.64) | PKMYT1GSK3BCDK2ABL1PDGFRB | |
| SCHEMBL3441857 | 0.79 | SLC2A1 (0.62) | PKMYT1GSK3BABL1PDGFRBBCR | |
| SCHEMBL3442825 | 0.77 | AURKA (0.72) | PKMYT1GSK3BABL1PDGFRBBCR | |
| SCHEMBL13105317 | 0.76 | SLC2A1 (0.57) | PKMYT1GSK3BCDK2CDK4 | |
| SCHEMBL3443186 | 0.75 | AURKA (0.60) | PKMYT1GSK3BCDK2CDK4DYRK1A | |
| SCHEMBL13105479 | 0.72 | SLC2A1 (0.52) | PKMYT1 | |
| SCHEMBL28276034 | 0.72 | USP2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812022-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1828185-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | PKMYT1 450/4885GSK3B 1240/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.